1-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoro-4-(hydroxyamino)pyrimidin-2-one | 13491-44-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoro-4-(hydroxyamino)pyrimidin-2-one
• CAS: 13491-44-6
• 化学式: C₉H₁₂FN₃O₆
• 分子量: 277.21
• InChiKey: FBGTUUWFXKRMTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING N4-HYDROXYCYTIDINE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF INFLUENZA OR CORONAVIRUS INFECTIONS
  申请人：Emory University

  公开号：EP3939985A1

  公开（公告）日：2022-01-19

  The present invention relates to pharmaceutical compositions comprising N4-hydroxycytidine derivatives of formula I for use in the treatment or prevention of infections caused by influenza virus including influenza A virus, subtype H1N1, H3N2, H7N9, or H5N1, influenza B virus, and influenza C virus, human coronavirus, and SARS coronavirus.

  本发明涉及由式 I 的 N4-羟基胞嘧啶衍生物组成的药物组合物 用于治疗或预防由流感病毒（包括甲型流感病毒、H1N1、H3N2、H7N9 或 H5N1 亚型、乙型流感病毒、丙型流感病毒、人类冠状病毒和 SARS 冠状病毒）引起的感染。
• N4-hydroxycytidine and derivatives and anti-viral uses related thereto
  申请人：Emory University

  公开号：US10874683B2

  公开（公告）日：2020-12-29

  This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.

  本公开涉及某些 N4-羟基胞嘧啶衍生物、组合物及其相关方法。 在某些实施方案中，本公开涉及寨卡病毒感染的治疗或预防。
• N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
  申请人：Emory University

  公开号：US20190022116A1

  公开（公告）日：2019-01-24

  This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.
• N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO
  申请人：EMORY UNIVERSITY

  公开号：US20200276219A1

  公开（公告）日：2020-09-03

  This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.